This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huse, B. Articles by Rusconi, S. Search for Related Content PubMed PubMed Citation Articles by Huse, B. Articles by Rusconi, S.

Definition of a Negative Modulation Domain in the Human Progesterone Receptor

Biochemistry Institute Université de Fribourg, Pérolles CH-1700 Fribourg, Switzerland

The progesterone receptor (PR) occurs in two major forms, the full-length PRB and the amino-truncated PRA, which lacks 164 amino-terminal residues. PRB functions as a strong transcriptional activator of progesterone-responsive genes, whereas PRA is inactive in several cell types where it may even act as a trans-dominant repressor of PRB and other steroid receptors, like the glucocorticoid receptor or, reportedly, the estrogen receptor. We initially observed that a PR deleted of its entire amino domain (PR538-C) is incapable of trans-repressing PRB or glucocorticoid receptor, suggesting that a negative modulation domain must be contained in the region between position 165 and 538. After testing progressive deletion mutants and chimeras, we demonstrate that this negative modulating domain is confined within 120 residues in the amino-terminal region and that it contains a subdomain of 40 residues that is crucial for intermolecular transrepression. Duplication, deletion, and transplantation of the negative modulation domain show that the negative modulation domain has only a limited functional autonomy. In our hands, transrepression of estrogen receptor could not be substantiated, and, under our conditions, at least an equimolar concentration of PRA expression plasmid is required for transrepression. Our deletion studies reveal domains that correlate with strong homology patches between the amino-terminal domains of mammalian and avian PR.

This article has been cited by other articles:

				I. Quiles, L. Millan-Arino, A. Subtil-Rodriguez, B. Minana, N. Spinedi, C. Ballare, M. Beato, and A. Jordan Mutational Analysis of Progesterone Receptor Functional Domains in Stable Cell Lines Delineates Sets of Genes Regulated by Different Mechanisms Mol. Endocrinol., June 1, 2009; 23(6): 809 - 826. [Abstract] [Full Text] [PDF]

				J. D. Graham, M. L. Yager, H. D. Hill, K. Byth, G. M. O'Neill, and C. L. Clarke Altered Progesterone Receptor Isoform Expression Remodels Progestin Responsiveness of Breast Cancer Cells Mol. Endocrinol., November 1, 2005; 19(11): 2713 - 2735. [Abstract] [Full Text] [PDF]

				J. Kim, C. A. Cantwell, P. F. Johnson, C. M. Pfarr, and S. C. Williams Transcriptional Activity of CCAAT/Enhancer-binding Proteins Is Controlled by a Conserved Inhibitory Domain That Is a Target for Sumoylation J. Biol. Chem., October 4, 2002; 277(41): 38037 - 38044. [Abstract] [Full Text] [PDF]

				H. Abdel-Hafiz, G. S. Takimoto, L. Tung, and K. B. Horwitz The Inhibitory Function in Human Progesterone Receptor N Termini Binds SUMO-1 Protein to Regulate Autoinhibition and Transrepression J. Biol. Chem., September 6, 2002; 277(37): 33950 - 33956. [Abstract] [Full Text] [PDF]

				J. Gao, J. Mazella, M. Tang, and L. Tseng Ligand-Activated Progesterone Receptor Isoform hPR-A Is a Stronger Transactivator Than hPR-B for the Expression of IGFBP-1 (Insulin-Like Growth Factor Binding Protein-1) in Human Endometrial Stromal Cells Mol. Endocrinol., December 1, 2000; 14(12): 1954 - 1961. [Abstract] [Full Text]

				J. A. Iñiguez-Lluhí and D. Pearce A Common Motif within the Negative Regulatory Regions of Multiple Factors Inhibits Their Transcriptional Synergy Mol. Cell. Biol., August 15, 2000; 20(16): 6040 - 6050. [Abstract] [Full Text]

				P. H. Giangrande, E. A. Kimbrel, D. P. Edwards, and D. P. McDonnell The Opposing Transcriptional Activities of the Two Isoforms of the Human Progesterone Receptor Are Due to Differential Cofactor Binding Mol. Cell. Biol., May 1, 2000; 20(9): 3102 - 3115. [Abstract] [Full Text]

				E. M. McGowan and C. L. Clarke Effect of Overexpression of Progesterone Receptor A on Endogenous Progestin-Sensitive Endpoints in Breast Cancer Cells Mol. Endocrinol., October 1, 1999; 13(10): 1657 - 1671. [Abstract] [Full Text]

				Q. Wang, J. Lu, and E. L. Yong Ligand- and Coactivator-mediated Transactivation Function (AF2) of the Androgen Receptor Ligand-binding Domain Is Inhibited by the Cognate Hinge Region J. Biol. Chem., March 2, 2001; 276(10): 7493 - 7499. [Abstract] [Full Text] [PDF]